Nurix Therapeutics Inc

NRIX remains in a Stage 2 advancing regime with an intact uptrend, but recent price is extended well above rising EMAs and marked by a bearish engulfing at new highs alongside extreme overbought RSI and Options Score readings. Short-term timing is unfavorable, so we defer execution and will stalk for a pullback into the 9/21 EMA support zone to participate in the next continuation leg.

• ↑Roche collaboration worth up to $2.3B adds cash and credibility
• ↑85.4% one-year shareholder return reflects robust investor confidence
• ↓Price-to-Sales at 33.3x far above peers raises valuation concerns